

# Lawrence S Lamb

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1043317/publications.pdf>

Version: 2024-02-01

49  
papers

1,456  
citations

430874

18  
h-index

361022

35  
g-index

50  
all docs

50  
docs citations

50  
times ranked

1901  
citing authors

#	ARTICLE	IF	CITATIONS
1	Improving the safety of cell therapy products by suicide gene transfer. <i>Frontiers in Pharmacology</i> , 2014, 5, 254.	3.5	165
2	Rapid Communication: Increased Frequency of TCR $\beta$ <sup>+</sup> T Cells in Disease-Free Survivors Following T Cell-Depleted, Partially Mismatched, Related Donor Bone Marrow Transplantation for Leukemia. <i>Stem Cells and Development</i> , 1996, 5, 503-509.	1.0	132
3	Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers. <i>Blood</i> , 2001, 98, 505-512.	1.4	132
4	Modeling Human Severe Combined Immunodeficiency and Correction by CRISPR/Cas9-Enhanced Gene Targeting. <i>Cell Reports</i> , 2015, 12, 1668-1677.	6.4	95
5	Cytotoxic and Regulatory Properties of Circulating V $\beta$ 1+ $\gamma$ $\delta$ T Cells: A New Player on the Cell Therapy Field?. <i>Molecular Therapy</i> , 2014, 22, 1416-1422.	8.2	93
6	$\gamma$ $\delta$ T cells: A new frontier for immunotherapy?. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 161-168.	2.0	75
7	In vivo expansion and activation of $\gamma$ $\delta$ T cells as immunotherapy for refractory neuroblastoma. <i>Medicine (United States)</i> , 2016, 95, e4909.	1.0	74
8	In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia. <i>PLoS ONE</i> , 2016, 11, e0166891.	2.5	72
9	Characterization and immunotherapeutic potential of $\gamma$ $\delta$ T-cells in patients with glioblastoma. <i>Neuro-Oncology</i> , 2009, 11, 357-367.	1.2	69
10	Engineered Drug Resistant $\gamma$ $\delta$ T Cells Kill Glioblastoma Cell Lines during a Chemotherapy Challenge: A Strategy for Combining Chemo- and Immunotherapy. <i>PLoS ONE</i> , 2013, 8, e51805.	2.5	68
11	Non-MHC-restricted cytotoxic cells: their roles in the control and treatment of leukaemias. <i>British Journal of Haematology</i> , 2001, 114, 11-24.	2.5	54
12	Characterization of the $\gamma$ $\delta$ T cell response to acute leukemia. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 1072-1080.	4.2	50
13	Preclinical evaluation of ex vivo expanded/activated $\gamma$ $\delta$ T cells for immunotherapy of glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 2011, 101, 179-188.	2.9	47
14	CMV-Independent Lysis of Glioblastoma by Ex Vivo Expanded/Activated V $\beta$ 1+ $\gamma$ $\delta$ T Cells. <i>PLoS ONE</i> , 2013, 8, e68729.	2.5	39
15	Efficacy of Therapeutic Group by Telephone for Women With Breast Cancer. <i>Cancer Nursing</i> , 2003, 26, 439-447.	1.5	37
16	Broad T-Cell Receptor Repertoire in T-Lymphocytes Derived from Human Induced Pluripotent Stem Cells. <i>PLoS ONE</i> , 2014, 9, e97335.	2.5	29
17	$\gamma$ $\delta$ T cells as immune effectors against high-grade gliomas. <i>Immunologic Research</i> , 2009, 45, 85-95.	2.9	26
18	Glioma Cells Display Complex Cell Surface Topographies That Resist the Actions of Cytolytic Effector Lymphocytes. <i>Journal of Immunology</i> , 2010, 185, 4793-4803.	0.8	26

#	ARTICLE	IF	CITATIONS
19	A combined treatment regimen of MGMT-modified $\hat{1}\hat{3}\hat{1}$ T cells and temozolomide chemotherapy is effective against primary high grade gliomas. Scientific Reports, 2021, 11, 21133.	3.3	22
20	The safety of allogeneic innate lymphocyte therapy for glioma patients with prior cranial irradiation. Cancer Immunology, Immunotherapy, 2015, 64, 551-562.	4.2	18
21	Dynamics of Circulating $\hat{1}\hat{3}\hat{1}$ T Cell Activity in an Immunocompetent Mouse Model of High-Grade Glioma. PLoS ONE, 2015, 10, e0122387.	2.5	17
22	Regulation of NKG2D Stress Ligands and Its Relevance in Cancer Progression. Cancers, 2022, 14, 2339.	3.7	17
23	Effect of dietary copper on colonic tumor production and aortic integrity in the rat. Journal of Surgical Research, 1987, 42, 503-512.	1.6	14
24	Colorectal cancer in animal modelsâ€”A review. Journal of Surgical Research, 1987, 43, 476-487.	1.6	14
25	Effect of HSV-IL12 Loaded Tumor Cell-Based Vaccination in a Mouse Model of High-Grade Neuroblastoma. Journal of Immunology Research, 2016, 2016, 1-10.	2.2	14
26	Mobilization of Hematopoietic Progenitor Cells for Autologous Transplantation Using Pegfilgrastim and Plerixafor: Efficacy and Cost Implications. Biology of Blood and Marrow Transplantation, 2019, 25, 233-238.	2.0	10
27	Hematologic aspects of myeloablative therapy and bone marrow transplantation. Journal of Clinical Laboratory Analysis, 2005, 19, 47-79.	2.1	9
28	Morphologic and Functional Characteristics of Alveolar Macrophages Following Cryopreservation. Cryobiology, 1995, 32, 344-357.	0.7	8
29	Clinical-scale manufacturing of $\hat{1}\hat{3}\hat{1}$ T cells for protection against infection and disease recurrence following haploidentical peripheral blood stem cell transplantation and cyclophosphamide gvhd prophylaxis. Bone Marrow Transplantation, 2018, 53, 766-769.	2.4	8
30	Hematopoietic cellular therapy: implications for the flow cytometry laboratory. Hematology/Oncology Clinics of North America, 2002, 16, 455-476.	2.2	6
31	T-cell lymphoblastic leukemia/lymphoma syndrome with eosinophilia and acute myeloid leukemia. Cytometry Part B - Clinical Cytometry, 2005, 65B, 37-41.	1.5	5
32	Impact of high-dose steroid premedication on the outcome of myeloablative T-cell replete haploidentical peripheral blood stem cell transplant. Bone Marrow Transplantation, 2018, 53, 1345-1348.	2.4	4
33	Phase II clinical trial of one dose of post-transplant cyclophosphamide for graft versus host disease prevention following myeloablative, peripheral blood stem cell, matched unrelated donor transplantation. American Journal of Hematology, 2021, 96, E396-E398.	4.1	4
34	Cryopreserved normal macrophages as a control for assays of macrophage function. In Vitro Cellular and Developmental Biology - Animal, 1999, 35, 64-66.	1.5	2
35	Favorable Immune Reconstitution Profile after Allogeneic Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide. Blood, 2016, 128, 2236-2236.	1.4	1
36	THINK YOU KNOW septic shock? Read this. Nursing, 1982, 12, 34-43.	0.3	0

#	ARTICLE	IF	CITATIONS
37	WHAT TO EXPECT WHEN YOUR PATIENT'S SCHEDULED FOR MITRAL VALVE REPLACEMENT. Nursing, 1985, 15, 58-67.	0.3	0
38	Persistence pays off for CD3+ T-cell therapies. Cytotherapy, 2013, 15, 397-398.	0.7	0
39	Improved Outcomes Following Drug-Resistant Immunotherapy in a Human Xenograft Model of Temozolomide-Resistant Glioblastoma Multiforme. Biology of Blood and Marrow Transplantation, 2015, 21, S240.	2.0	0
40	Paradigm shifts in the management of poor-risk chronic lymphocytic leukemia. Leukemia and Lymphoma, 2015, 56, 1626-1635.	1.3	0
41	IMMU-15. ENGINEERED-DRUG RESISTANT GAMMA-DELTA (CD3+) T CELLS COMBINED WITH IMMUNE CHECKPOINT BLOCKADE AUGMENTED KILLING OF CANCER CELLS. Neuro-Oncology, 2018, 20, vi124-vi124.	1.2	0
42	Therapeutic Potential of Cells of the Immune System. , 2020, , 41-67.		0
43	Use of Dexamethasone Given to Sibling Donors as a Way of In Vivo Purging of Allo Reactive Donor T Cells in rhg-CSF Mobilized Peripheral Blood Stem Cell Transplantations Resulted in Significant Decrease in CD3+ Cells and Increased CD34+ Yield.. Blood, 2007, 110, 3047-3047.	1.4	0
44	ASBMT Risk Group and CD 34+ Dose Predicted for the Development of aGVHD in Allogeneic MRD Transplants When the Donors Who Received a Combined Mobilization and In Vivo TCD Regimen Using rhg-CFS and Dexamethasone.. Blood, 2007, 110, 5006-5006.	1.4	0
45	Abstract 1942: CD3+ T cells are cytotoxic against glioblastoma multiforme. , 2010, , .		0
46	Abstract 530: Circulating CD3+ T cells are activated and depleted during progression of high-grade gliomas: Implications for CD3+ T cells therapy of GBM. , 2012, , .		0
47	Abstract 643A: Characterization of the CD3+ T-cell response in high-grade glioma. , 2014, , .		0
48	Immune Reconstitution and Chimerism in Allogeneic HSCT Patients Treated with Post-HSCT High Dose Cyclophosphamide As Prophylaxis Against GvHD. Blood, 2014, 124, 2474-2474.	1.4	0
49	Recovery of CMV-Specific T Cells Following Alternative Donor Allogeneic Transplant with Post-Transplant Cyclophosphamide. Blood, 2015, 126, 5462-5462.	1.4	0